NasdaqCM - Delayed Quote USD

ImmunoPrecise Antibodies Ltd. (IPA)

0.5700
-0.0042
(-0.73%)
At close: May 30 at 4:00:01 PM EDT
0.5750
+0.00
+(0.88%)
After hours: May 30 at 7:55:26 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IPA

Recent News: IPA

View More
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
Business Wire 10 days ago
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
Business Wire 11 days ago
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
Business Wire 19 days ago
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
Business Wire last month
ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024)

ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024)
Simply Wall St. 2 months ago
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
Business Wire 2 months ago
Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock

Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock
Simply Wall St. 2 months ago
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
Business Wire 2 months ago
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
Business Wire 2 months ago
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
Business Wire 2 months ago
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
Business Wire 3 months ago
View More

Related Tickers

SLXN Silexion Therapeutics Corp
1.0400
+8.33%
 
SILO Silo Pharma, Inc.
0.4444
-5.97%
 
TNFA TNF Pharmaceuticals, Inc.
0.1604
-3.14%
 
INDP Indaptus Therapeutics, Inc.
0.3380
-15.50%
 
ELEV Elevation Oncology, Inc.
0.3001
-1.96%
 
WINT Windtree Therapeutics, Inc.
0.7610
-3.67%
 
ABP Abpro Corporation
0.2137
-8.28%
 
CERO CERo Therapeutics Holdings, Inc.
0.4454
-13.85%
 
GOVX GeoVax Labs, Inc.
1.0200
-4.67%
 
ABOS Acumen Pharmaceuticals, Inc.
1.0200
-2.86%